Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of iadademstat in hydroxyurea-resistant or -intolerant essential thrombocythemia
2025-523864-19-00Phase 2Authorised
- Sponsor
- Oryzon Genomics
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iadademstat in thrombocythemia, sponsored by Oryzon Genomics. Primary endpoints: Platelet response without thrombosis and Treatment-emergent adverse events. Planned start Feb 2026; status: authorised.
02
Drugs
iadademstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2025-523864-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523864-19-00.